Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss discussion includes Latanoprost as potential treatment. Mild improvement observed with its use.

Pyrilutamide's effect on sebum production and scalp inflammation is unclear, with users noting no significant changes. Isotretinoin is mentioned as effective for reducing sebum, while Dutasteride and various shampoos have limited impact on oiliness and seborrheic dermatitis.

User "Ant1pal" shares progress pictures of hair regrowth using Minoxidil, Estradiol valerate, and Spironolactone. Users discuss potential side effects and the possibility of localizing estrogen to hair follicles for better treatment.

Topical estradiol may help with hair loss but can have systemic effects, like reduced testosterone production. Using estrogen blockers can have negative side effects, such as joint pain and reduced sex drive.

User tried topical fin, dut, min, tret, hydrocortisone, microneedling, nizoral, collagen, propidren supplements, and laser helmet for hair loss with slow progress. They ask if topical spironolactone is a safer, effective alternative to RU for suppressing testosterone and treating hair loss in men.

A user offers an extra bottle of Koshine 0.5% solution for hair loss. The discussion involves interest in trying Pyrilutamide for hair treatment.

The conversation discusses potential hair loss treatments, including Setipiprant, Bimatoprost, and Follicept. The user encourages signing up for Follicept, which may come to market soon.

People are discussing their reactions if PP405 fails in phase 3 trials, with some expressing skepticism and others holding onto hope for future treatments like GT20029 and Breezula. Many mention continuing with existing treatments like minoxidil and finasteride, while others express disappointment and consider alternative solutions.

After nearly four months on finasteride, a user noticed improved hair quality but developed nipple puffiness, suggesting early signs of gynecomastia. They considered switching to other treatments like CB-03-01 or RU58841 and contemplated consulting an endocrinologist about aromatase inhibitors.

Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.

User used Finasteride, Dutasteride, and Minoxidil for one year to treat hair loss. They discussed possibly trying RU58841 or pyrilutamide in the future.

RU-58642 is a powerful anti-androgen that was not developed further, possibly due to safety concerns or financial reasons. RU58841 is a topical alternative, but it is less effective than finasteride and dutasteride, and its long-term effects are not well-studied.

The user experienced a significant drop in libido and erectile issues after increasing their finasteride dosage, combining oral and topical treatments. They plan to take a break and resume using a lower concentration of topical finasteride to manage side effects.

The user is considering reducing RU58841 dosage from 100mg to 17.5mg for long-term safety due to brain fog issues from finasteride. They apply RU58841 only to the front of the scalp where thinning occurs.

A user is considering starting spironolactone for androgenetic alopecia but is concerned about stopping it before pregnancy. Another user suggests trying topical treatments as an alternative.

The user is trying a new hair loss regimen including Spirolactone, Finasteride, oral Minoxidil, microneedling, and various supplements. They are experiencing increased shedding and seeking advice on microneedling and treatment effectiveness.

A 27-year-old male is experiencing a recurring pattern of hair loss after 5 months of using oral minoxidil and finasteride, despite initial success. He is considering using topical androgen receptor blockers like RU58841, pyrilutamide, or clascoterone to address potential androgen receptor hypersensitivity.

PP405 shows some hair growth after 4 weeks, but results are debated and expectations should be tempered. Some users compare it to minoxidil or finasteride, questioning its effectiveness and commercialization timeline.

Breezula (clascoterone) is expected to be available by late 2026, showing good long-term results with minimal side effects. KX-826 (pyrilutamide) acts faster but is still in earlier development stages.

A user diagnosed with lymphoma is advised to stop finasteride during chemotherapy, with suggestions to consider treatments like Dutasteride and Minoxidil post-recovery. The focus is on prioritizing health over hair loss, with encouragement and advice from others who have experienced similar situations.

A 20-year-old female is using finasteride 5mg and spironolactone 100mg for severe hirsutism and is experiencing minor side effects like water weight loss and irregular periods. She is concerned about potential future side effects and hair regrowth on her scalp.

Potential treatments for hair loss, specifically the combination of liquid minoxidil and pyrilutamide, with some suggesting that adding finasteride may be beneficial.

Latanoprost at 0.1% concentration is used to increase hair counts, often mixed with Minoxidil and Finasteride. Users report noticeable results in about 3 months.

The user stopped finasteride for family planning but plans to restart it and is considering dutasteride. Users discuss the safety of finasteride during family planning, with some sharing experiences of having healthy children while on the medication.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. User seeks updates on topical treatment Pyrilutamide.

GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.

RU58841 had mixed results for hair regrowth, with some users experiencing no change and others noting regrowth but also side effects like libido issues and chest pain. Some users combined it with other treatments like finasteride and dutasteride, with varying effectiveness.

A 51-year-old woman switched from Minoxidil to Maneup, a copper peptide treatment, experiencing initial hair loss but later regrowth with different hair texture. Users debated Maneup's effectiveness, with some considering it alongside finasteride.

The user experienced significant hair shedding after long-term use of finasteride and dutasteride and is now considering trying RU58841 as a last resort. They have checked health factors and suspect stress and poor sleep may contribute to the shedding, but they are determined to try RU58841 to see if it helps with androgenetic alopecia.

A user reported a significant increase in testosterone and estradiol levels after taking Finasteride for 5 months, with estradiol levels rising over 2000%. They plan to consult their doctor, suspecting a lab error, as they feel fine with no side effects.